Status:
COMPLETED
Macrophage Inhibitory Factor and High-Mobility Group-1 Protein in Children Undergoing Cardiopulmonary Bypass
Lead Sponsor:
University of Texas Southwestern Medical Center
Collaborating Sponsors:
Children's Medical Center Dallas
Conditions:
Myocardial Depression
Eligibility:
All Genders
Up to 5 years
Brief Summary
Introduction: In recent scientific literature, 2 proteins, macrophage migration inhibitory factor (MIF) and high-mobility group-1 protein (HMG-1), have emerged as important mediators of inflammation a...
Detailed Description
PURPOSE: To document the presence or absence of the proinflammatory cytokines macrophage migration inhibitory factor (MIF) and high-mobility group-1 protein (HMG-1) in the serum and myocardium of chil...
Eligibility Criteria
Inclusion
- Any child under the age of 5 undergoing operative repair of congenital heart disease on CPB where there is an expectation of cardiac tissue removal.
- Written informed consent obtained from a parent/legal guardian.
Exclusion
- Unable to obtain informed consent
- Evidence of ongoing infection
- Known immunodeficiency
Key Trial Info
Start Date :
September 1 2001
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00692432
Start Date
September 1 2001
End Date
December 1 2008
Last Update
May 10 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Medical Center Dallas
Dallas, Texas, United States, 75235